Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCT-808 in Aggressive B-Cell Malignancies
NCT05588440Phase 2Terminated
- Sponsor
- Oncternal Therapeutics
- Start
- May 2023
- Primary completion
- Sep 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of ONCT-808 in aggressive B-cell lymphoma, mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), sponsored by Oncternal Therapeutics. Started May 2023; status: terminated.
02
Drugs
ONCT-808
03
Conditions
aggressive B-cell lymphomamantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05588440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05588440.